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REVIEW
Abstract: Poorly controlled asthma is currently treated by adding or removing asthma
medication in a stepwise fashion to try and improve symptoms and maintain lung function. It
is becoming apparent that asthma exacerbations are independent of asthma control and severity,
and that the simple method of using rescue courses of corticosteroids to treat an asthma
exacerbation can be bettered by aiming to prevent its occurrence. New tools that can predict
and prevent exacerbations are now becoming available. This article discusses these tools and
takes a more detailed look at new treatment regimes being used.
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Introduction
The medical, social, and financial costs of poorly controlled asthma are huge. A
survey by Asthma UK found that 5.2 million people in the UK have asthma, which
led to over 1400 deaths in 2002. The financial cost of asthma to the UK is over
£2.3 billion per year. Studies have consistently shown that poorly controlled asthma
costs a great deal more than well controlled asthma. For example, Hoskins et al
(2000) found the average cost per patient was 3.5 times higher for a patient having
an asthma attack, compared with a patient who did not. Similar figures have been
presented by Van Ganse et al (2002). Barnes et al (1996) suggested there was
significant scope for cost reduction by improving disease control, and that a third of
the direct cost of asthma is related to emergency room use, hospitalization, and death.
Severity versus control
Asthma treatment guidelines aim to improve asthma symptoms and prevent
exacerbations (ATS 2000; Bousquet 2000; BTS and SIGN 2003), but the definitions
differ for asthma deteriorations, severity, and control. One of the best definitions of
asthma severity and control was published by Cockcroft and Swystun (1996), who
defined asthma severity as the minimum medication (inhaled or oral corticosteroids)
required to achieve asthma control. Control was defined as lack of symptoms, normal
lifestyle, near normal lung function, and lack of morbidity; the implication being
that once a patient has good asthma control there should be little resting
bronchoconstriction and little response to bronchodilator. This definition separates
severity from control and allows the proper categorization of patients in clinical
trials. A patient may have mild but poorly controlled asthma; having symptoms that
are easily preventable by administration or increase in their corticosteroid dose.
Conversely, a patient may have severe but well controlled asthma, requiring continuous
high dose inhaled or oral corticosteroids to remain asymptomatic (Cockcroft and
Swystun 1996).
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Asthma exacerbations
Defining asthma exacerbations is problematic and should
be separate from control and severity. Reddel et al (1999)
compared peak flow patterns during asthma exacerbations
with periods of poor asthma control. Peak flow variation
was strikingly different during an asthma exacerbation when
compared with episodes of poor asthma control, falling, and
improving linearly over several days, whereas episodes of
poor asthma control were characterised by morning dipping,
wide diurnal variability, and by an impressive bronchodilator
response. However, there was no difference in peak flow
diurnal variability during asthma exacerbations compared
with episodes of poor asthma control, which suggests this
commonly measured parameter may fail to detect important
changes in lung function. During asthma exacerbations there
was also an impaired response to inhaled β2 agonist. This
failure of response to a β2 agonist therefore appears to
delineate poor asthma control from an asthma exacerbation.
The study also demonstrated that patients with well
controlled asthma were still prone to asthma exacerbations
(Reddel et al 1999). Criteria used in studies to define an
exacerbation include: peak flow dropping from a pre-
determined baseline; need for rescue oral corticosteroids;
an increase in the use of rescue β2 agonist; night time
awakening; or increased symptom scores.
The incidence of asthma exacerbations in studies varies
with the definition used and the baseline severity and control
of the population being studied. In the Formoterol and
Corticosteroids Establishing Therapy International Study
Group (FACET) study designed to evaluate the benefits of
adding a long acting β2 agonist to different doses of inhaled
corticosteroid, a severe exacerbation was defined as an
episode requiring treatment with oral corticosteroids, as
judged by the investigator, or a decrease in the morning
peak flow to more than 30% below the baseline value
(established during the run-in period) on 2 consecutive days
(Pauwels et al 1997). Mild exacerbations were defined as at
least 2 consecutive days with a peak flow 20% less than
baseline, or nocturnal awakening, or 3 additional inhalations
of terbutaline, when compared with the run-in period.
Approximately 850 patients entered the study and were
randomized into one of four groups. The total number of
severe exacerbations was 425 over a 12-month period, giving
an overall exacerbation rate of 0.5 exacerbations/patient/
year. The total number of mild exacerbations was a massive
16 463. In the Gaining Optimal Asthma ControL study, a
combination of salmeterol/fluticasone (as Seretide®) was
compared with fluticasone alone in 3 different groups of
patients over the course of one year. The baseline
characteristics revealed that there were 3416 patients who
experienced 1832 exacerbations, defined as hospitalization
or requiring a course of antibiotics or oral corticosteroids,
giving an overall exacerbation rate of 0.54 exacerbations/
patient/year before entry into the study proper (Bateman et
al 2004). These rough figures demonstrate that severe asthma
exacerbations are common and that adding in a long-acting
β2 agonist reduces asthma exacerbations. The FACET study
also revealed that higher dose inhaled corticosteroids have
a marked beneficial effect on exacerbation frequency but
relatively less effect on symptoms and peak expiratory flow,
whereas with the addition of long-acting β2-agonists, the
opposite was true (Pauwels et al 1997; Tattersfield et al
1999).
This indicates that exacerbation frequency does not
closely relate to symptoms and measures of disordered
airway function, suggesting that the mechanisms responsible
for these features of asthma are different. Rosi et al (1999)
also found that asthma exacerbation frequency does not
relate closely to symptoms and measures of disordered
airway function. This demonstrates that different strategies
are needed to reduce asthma exacerbations, as well as
optimise asthma control.
Treatment strategies
The current strategy recommended by the British Thoracic
Society (BTS) suggests a stepwise approach to asthma
control and exacerbations (BTS and SIGN 2003). However,
patients who appear clinically well controlled on inhaled
corticosteroids can still have evidence of airway inflam-
mation and airway hyperresponsiveness (Boulet et al 1994;
Sont et al 1996) and be vulnerable to exacerbations, airway
remodeling, and possibly fixed airways obstruction (Lange
et al 1998; Beckett and Howarth 2003). Self management
plans advocate doubling the dose of inhaled corticosteroid
if the peak flow drops. This approach has recently been
questioned. Harrison et al (2004) found that doubling the
dose of inhaled corticosteroid, based on a fall in peak flow
of > 15% from baseline or an increase in the symptom score
from baseline, did not prevent the need for oral
corticosteroids. The authors surmised that a higher dose of
inhaled corticosteroid may be needed to prevent an asthma
exacerbation. Indeed, Foresi et al (2000) demonstrated that
increasing (quadrupling) the inhaled corticosteroid dose at
the onset of an asthma exacerbation had a beneficial clinical
effect and reduced the requirement for oral corticosteroids
compared with placebo. This suggests that it is not too lateTherapeutics and Clinical Risk Management 2005:1(4) 275
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for an exacerbation to be attenuated while peak flow or
symptoms are deteriorating.
Other strategies that focus on the pathophysiological
features of asthma have been tried with some success. Sont
et al (1999) investigated a treatment strategy focused on
reducing airway hyperresponsiveness in mild and moderate
asthma in addition to the recommendations of the asthma
guidelines at the time. Seventy-five adults with mild to
moderate asthma were studied in a randomized prospective
parallel trial. One group had their treatment adjusted
according to the normal reference strategy. The other group
had their treatment adjusted according to their degree of
airway hyperresponsiveness. The treatment strategy based
on attempting to return airway responsiveness towards
normal reduced both exacerbations and subepithelial
reticular basement membrane thickening. Patients treated
by the airway hyperresponsiveness protocol had a 1.8-fold
decrease in mild exacerbations when compared with the
reference group. The authors concluded that monitoring
airway hyperresponsiveness or other surrogate markers of
airway inflammation may help in the long-term management
of asthma.
Green et al (2002) directly tested this hypothesis with a
management approach that both measured and attempted
to normalize eosinophilic airway inflammation, as well as
minimize symptoms and maximize lung function. Seventy-
four subjects attending outpatients with moderate to severe
asthma were randomized to treatment either according to
the BTS guidelines or to a management strategy where
treatment was adjusted according to the sputum eosinophil
counts. In the sputum management group, decisions about
antiinflammatory treatment were made in accordance with
an algorithm based on control of symptoms and maintenance
of the sputum eosinophil count at or below 3% with a
minimum dose of antiinflammatory treatment. The 3% cut-
off was chosen because this was previously shown to identify
individuals with corticosteroid-responsive asthma (Pavord
et al 1999). If the sputum eosinophil count was less than
1%, antiinflammatory treatment was reduced irrespective
of asthma control. If the eosinophil count was 1%–3%, no
changes to antiinflammatory treatment were made, and if
the eosinophil count was greater than 3%, antiinflammatory
treatment was increased. Decisions about changes in
bronchodilator treatment were based on individual patients’
symptoms, peak expiratory flow readings, and use of rescue
β2 agonists compared with baseline using the same criteria
as in the BTS management group. Management decisions
were made by an independent individual who was unaware
Figure 1 Comparison of effects of two treatment strategies on symptoms
score (assessed by visual analogue score [VAS]). Asthma quality of life
questionnaire (AQLQ), β2 agonist use to relieve asthma symptoms, peak
expiratory flow, and post-bronchodilator forced expiratory volume in 1 second
(FEV1). One strategy (British Thoracic Society [BTS] management group) utilized
standard BTS guidelines and the other (sputum management group) adjusted the
antiinflammatory treatment with corticosteroids based on the eosinophil
counts. Source: Green RH, Brightling CE, McKenna S, et al. 2002. Asthma
exacerbations and sputum eosinophil counts: a randomised controlled trial.
Lancet, 360:1715–21. Copyright © 2004. Reprinted with permission from Elsevier.Therapeutics and Clinical Risk Management 2005:1(4) 276
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of the clinical characteristics of the patient, and who recorded
separate treatment plans to be followed depending on
whether the patients’ asthma was poorly or well controlled.
The strategy based on sputum eosinophil counts achieved
significantly better control of eosinophilic related airway
inflammation over the twelve-months of the trial. There was
also an improvement in methacholine PC20 (Figure 1). Both
management strategies achieved equivalent control of
symptoms, quality of life, and disordered airway function.
Importantly, in the sputum management group there was a
marked reduction in severe asthma exacerbations and
significantly fewer hospital admissions with asthma
exacerbations. There were 109 severe exacerbations in the
BTS group, compared with 35 in the sputum group and 6
asthma admissions in the BTS group, with 1 in the sputum
group (Figure 2).
New approaches
Unfortunately, given the resource implications and need for
rapid sputum processing, a sputum management protocol
is only really suitable for secondary care. According to
Asthma UK, only approximately 18% of patients with
asthma are seen in hospital outpatients; there is therefore a
need for a simpler measure of airway inflammation that is
applicable in a primary care setting.
An approach using measurements of nitric oxide in the
exhaled breath may have clinical utility; although there are
no published trials yet on the real world applicability of
exhaled nitric oxide in reducing asthma exacerbations,
several authors have noted that a rise in the fraction of
exhaled nitric oxide (FeNO) in the exhaled breath of patients
with asthma seems to predict exacerbations. Harkins et al
(2004) also monitored FeNO levels in a group of 22 patients
with moderate and severe persistent asthma and found that
those patients suffering an asthma exacerbation within
2 weeks of the initial visit had a higher mean FeNO at
the initial visit. Jones et al (2001) withdrew inhaled
corticosteroids aiming to induce loss of asthma control. They
found that change in FeNO levels from baseline and FeNO
levels at the prior visit were both good markers of impending
loss of control, suggesting that FeNO may rise early enough
for a therapeutic intervention to be of value. However, the
study end point was loss of control, the definition of which
was comparable to a mild exacerbation in the FACET study
(Tattersfield et al 1999), rather than asthma exacerbation.
Recently, new treatment regimes have been suggested
to improve asthma control and prevent asthma exacerbations.
O’Byrne et al (2005) evaluated the use of budesonide and
formoterol (combined as Symbicort
®) as maintenance and
reliever therapy (SMART), compared with budesonide/
formoterol fixed dose therapy and high dose budesonide.
SMART reduced the number of exacerbations when
compared with fixed dose therapy. As noted in an excellent
editorial by Gibson (2005), this approach might lead to over-
or under-treatment of asthma so caution must be used when
using SMART beyond the study entry criteria of moderate
persistent asthma with poor symptom control despite inhaled
corticosteroid therapy. Keeping this in mind, one other
indication for SMART may be in the treatment of poorly
concordant patients (Sovani et al 2004).
Conclusion
Asthma can differ in its severity, control, and exacerbation
pattern. Categorizing asthma in this way is not just important
for study outcomes, but also for patient care. Asthma
exacerbations are common and costly and can be
characterized as not responding to increased inhaled β2
agonist use. Most importantly, they can be prevented by
decreasing the airway inflammatory response with prompt
and judicious use of corticosteroids. Identifying the precise
time and proper dose of corticosteroid is becoming easier,
using methods such as induced sputum and FeNO. Rather
than be reactive to an asthma exacerbation, these tools allow
proactive intervention which prevent exacerbations
developing. Currently, FeNO looks to be the most practical
method for predicting asthma exacerbations. Key questions
remain: What factor in the lung is FeNO telling us most
about? What is the “normal” level of FeNO for a patient
Figure 2 Comparison of effects of two treatment strategies on rates of severe
exacerbations of asthma. One strategy (British Thoracic Society [BTS]) utilized
standard BTS guidelines and the other (sputum management group) adjusted the
antiinflammatory treatment with corticosteroids based on the eosinophil
counts. Source: Green RH, Brightling CE, McKenna S, et al. 2002. Asthma
exacerbations and sputum eosinophil counts: a randomised controlled trial.
Lancet, 360:1715–21. Copyright © 2004. Reprinted with permission from Elsevier.Therapeutics and Clinical Risk Management 2005:1(4) 277
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with asthma? As with most conditions in medicine,
prevention may be better than cure.
References
[ATS] American Thoracic Society. 2000. Proceedings of the ATS workshop
on refractory asthma: current understanding, recommendations, and
unanswered questions. Am J Respir Crit Care Med, 162:2341–51.
Barnes PJ, Jonsson B, Klim JB. 1996. The costs of asthma. Eur Respir J,
9:636–42.
Bateman ED, Boushey HA, Bousquet J, et al. 2004. Can guideline-defined
asthma control be achieved? The Gaining Optimal Asthma ControL
study. Am J Respir Crit Care Med, 170:836–44.
Beckett PA, Howarth PH. 2003. Pharmacotherapy and airway remodelling
in asthma? Thorax, 58:163–74.
Boulet LP, Turcotte H, Brochu A. 1994, Persistence of airway obstruction
and hyperresponsiveness in subjects with asthma remission. Chest,
105:1024–31.
Bousquet J. 2000. Global initiative for asthma (GINA) and its objectives.
Clin Exp Allergy, 30(Suppl 1):2–5.
[BTS and SIGN] British Thoracic Society, Scottish Intercollegiate
Guidelines Network. 2003. British guideline on the management of
asthma. Thorax, 58(Suppl 1):i1–94.
Cockcroft DW, Swystun VA. 1996. Asthma control versus asthma severity.
J Allergy Clin Immunol, 98:1016–18.
Foresi A, Morelli MC, Catena E; on behalf of the Italian Study Group.
2000. Low-dose budesonide with the addition of an increased dose
during exacerbations is effective in long-term asthma control. Chest,
117:440–6.
Gibson PG. 2005. Teaching old drugs new tricks: asthma therapy adjusted
by patient perception or noninvasive markers. Eur Respir J, 25:
397–9.
Green RH, Brightling CE, McKenna S, et al. 2002. Asthma exacerbations
and sputum eosinophil counts: a randomised controlled trial. Lancet,
360:1715–21.
Harkins MS, Fiato KL, Iwamoto GK. 2004. Exhaled nitric oxide predicts
asthma exacerbation. J Asthma, 41:471–6.
Harrison TW, Oborne J, Newton S, et al. 2004. Doubling the dose of inhaled
corticosteroid to prevent asthma exacerbations: randomised controlled
trial. Lancet, 363:271–5.
Hoskins G, McCowan C, Neville RG, et al. 2000. Risk factors and costs
associated with an asthma attack. Thorax, 55:19–24.
Jones SL, Kittelson J, Cowan JO, et al. 2001. The predictive value of
exhaled nitric oxide measurements in assessing changes in asthma
control. Am J Respir Crit Care Med, 164:738–43.
Lange P, Parner J, Vestbo J, et al. 1998. A 15-year follow-up study of
ventilatory function in adults with asthma. N Engl J Med, 339:
1194–200.
O’Byrne PM, Bisgaard H, Godard PP, et al. 2005. Budesonide/formoterol
combination therapy as both maintenance and reliever medication in
asthma. Am J Respir Crit Care Med, 171:129–36.
Pauwels RA, Lofdahl CG, Postma DS, et al. 1997. Effect of inhaled
formoterol and budesonide on exacerbations of asthma. Formoterol
and Corticosteroids Establishing Therapy (FACET) International Study
Group. N Engl J Med, 337:1405–11.
Pavord ID, Brightling CE, Woltmann G, et al. 1999. Non-eosinophilic
corticosteroid unresponsive asthma. Lancet, 353:2213–14.
Reddel H, Ware S, Marks G, et al. 1999. Differences between asthma
exacerbations and poor asthma control. Lancet, 353:364–9.
Rosi E, Ronchi MC, Grazzini M, et al. 1999. Sputum analysis, bronchial
hyperresponsiveness, and airway function in asthma: results of a factor
analysis. J Allergy Clin Immunol, 103:232–7.
Sont JK, Han J, van Krieken JM, et al. 1996. Relationship between the
inflammatory infiltrate in bronchial biopsy specimens and clinical
severity of asthma in patients treated with inhaled steroids. Thorax,
51:496–502.
Sont JK, Willems LN, Bel EH, et al. 1999. Clinical control and
histopathologic outcome of asthma when using airway
hyperresponsiveness as an additional guide to long-term treatment.
The AMPUL Study Group. Am J Respir Crit Care Med, 159:
1043–51.
Sovani MP, Whale CI, Oborne J, et al. 2004. The effect of providing a
single inhaler containing formoterol and budesonide to be used once
daily and as required on inhaled budesonide use and asthma control
in poorly compliant patients [abstract]. Thorax, 59:ii11:1–12.
Tattersfield AE, Postma DS, Barnes PJ, et al. 1999. Exacerbations of
asthma: a descriptive study of 425 severe exacerbations. The FACET
International Study Group. Am J Respir Crit Care Med, 160:594–9.
Van Ganse E, Laforest L, Pietri G, et al. 2002. Persistent asthma: disease
control, resource utilisation and direct costs. Eur Respir J, 20:260–7.